


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

INSIDE INFORMATION
TERMINATION OF LISTING TUTORIAL

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Hong Kong Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 3 February 2021 (the “**Announcement**”) in relation to the possible issue of RMB Shares and listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board hereby announces that due to the prevailing market conditions and having considered the future development plans of the Company, the Company has resolved not to proceed further with the Proposed Domestic Issue. The Company and the listing tutorial institutions have mutually agreed to terminate the listing tutorial agreement and all tutorial work thereunder (the “**Listing Tutorial**”) in respect of the Proposed Domestic Issue, and have reported to the CSRC (Beijing Branch) about the termination. The Company will take into consideration the market conditions and its own development requirements and make plans for other arrangements in the future.

The Board is of the view that the Company not proceeding further with the Proposed Domestic Issue will not have any material adverse impact on the business, operation and financial position of the Company, nor will it prejudice the interest of the Company and the Shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 8 February 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.